沃华医药涨2.09%，成交额1.30亿元，主力资金净流出667.13万元

Core Viewpoint - Wohuah Pharmaceutical has shown a significant increase in stock price and financial performance, indicating potential growth opportunities in the pharmaceutical sector, particularly in traditional Chinese medicine [1][2]. Group 1: Stock Performance - As of January 14, Wohuah Pharmaceutical's stock price increased by 2.09% to 7.32 CNY per share, with a total market capitalization of 4.225 billion CNY [1]. - The stock has risen by 17.31% year-to-date, with a 5-day increase of 8.44%, a 20-day increase of 18.64%, and a 60-day increase of 16.19% [1]. Group 2: Financial Performance - For the period from January to September 2025, Wohuah Pharmaceutical reported a revenue of 625 million CNY, representing a year-on-year growth of 8.31% [2]. - The net profit attributable to shareholders for the same period was 63.995 million CNY, showing a substantial year-on-year increase of 179.34% [2]. Group 3: Shareholder Information - As of September 30, 2025, the number of shareholders increased to 41,000, up by 17.18%, while the average number of circulating shares per person decreased by 14.66% to 13,892 shares [2]. - The company has distributed a total of 692 million CNY in dividends since its A-share listing, with 214 million CNY distributed over the past three years [3]. Group 4: Business Overview - Wohuah Pharmaceutical, established in 2002 and listed in 2007, specializes in the research, production, and sales of natural plant-based cardiovascular traditional Chinese medicine [1]. - The company's revenue composition includes 69.17% from cardiovascular drugs, 23.46% from musculoskeletal drugs, 3.59% from other categories, 2.97% from antiviral respiratory drugs, and 0.81% from reproductive and urinary system drugs [1].